|
|
Recent Articles
-
Ameresco’s Backlog Continues to Build
Nov 11, 2024
-
Image: Ameresco’s backlog of future business remains strong and growing.
Looking to full year 2024 guidance, Ameresco expects revenue in the range of $1.7-$1.8 billion, up 27% at the midpoint of the range. Gross margin is targeted in the range of 16%-16.5%, while adjusted EBITDA is targeted to grow 35% at the midpoint of the range, to $210-$230 million. Non-GAAP earnings per share is targeted in the range of $1.15-$1.35. We continue to like Ameresco’s backlog build, as we continue to monitor its debt position and adjusted operating cash flow trends closely. The firm remains an idea in the ESG Newsletter portfolio.
-
Dividend Increases/Decreases for the Week of November 8
Nov 8, 2024
-
Let's take a look at firms raising/lowering their dividends this week.
-
Energy Transfer Now Covers Distributions with Traditional Free Cash Flow
Nov 7, 2024
-
Image: Energy Transfer’s units have done quite well the past couple years, as the pipeline giant now covers distributions with traditional free cash flow.
For the nine months ended September 30, Energy Transfer generated $8.9 billion in cash flow from operations, as it spent $2.7 billion in capital expenditures, resulting in traditional free cash flow generation of $6.2 billion, which is well in excess of its distributions to partners, noncontrolling interests, and redeemable noncontrolling interests of $4.9 billion. Energy Transfer ended the third quarter with $299 million in cash and total debt of $59.3 billion. We liked Energy Transfer’s third quarter results, and we’re huge fans of its newfound ability to cover distributions with traditional free cash flow.
-
Gilead Raises Revenue and Non-GAAP Diluted EPS Guidance
Nov 7, 2024
-
Image Source: Gilead.
At the end of the quarter, Gilead had $5 billion in cash and marketable securities compared to $8.4 billion at the end of the year, the decline primarily due to its $3.9 billion acquisition of CymaBay Therapeutics. For the full year 2024, Gilead raised its guidance for product sales to the range of $27.8-$28.1 billion, up from $27.1-$27.5 billion previously. Non-GAAP diluted earnings per share is now targeted in the range of $4.25-$4.45, up from $3.60-$3.90 previously. We liked Gilead’s revenue growth in the quarter, as well as its raised financial outlook for 2024. The high end of our fair value estimate range stands at $111 per share.
|
